NASDAQ:ICLRIcon Stock Price, Forecast & News

$170.77

+2.32 (+1.38 %)

(As of 06/1/2020 02:32 PM ET)

Add

Compare

Today's Range

$167.36

Now: $170.77▼

$172.15

50-Day Range

$148.90

MA: $157.29▼

$167.70

52-Week Range

$104.28

Now: $170.77▼

$178.99

Volume6,286 shs

Average Volume240,664 shs

Market Capitalization$9.16 billion

P/E Ratio25.15

Dividend YieldN/A

Beta0.86

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. Its clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. The company was founded in 1990 and is headquartered in Dublin, Ireland.

Beat the Market (BTM) Rank^™

2.2 Analyst's Opinion

Consensus Rating
Icon has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on 5 buy ratings, 6 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $159.18, Icon has a potential downside of 6.8% from its current price of $170.77.
Amount of Analyst Coverage
Icon has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.6 Community Rank

Outperform Votes
Icon has received 539 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Icon has received 517 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Icon has received 51.04% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Icon and other stocks. Vote “Outperform” if you believe ICLR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ICLR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Icon does not currently pay a dividend.
Dividend Growth
Icon does not have a long track record of dividend growth.

2.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Icon insiders have not sold or bought any company stock.
Percentage Held by Insiders
44.00% of the stock of Icon is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
82.71% of the stock of Icon is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Icon are expected to grow by 27.85% in the coming year, from $5.71 to $7.30 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Icon is 25.15, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.52.
Price to Earnings Ratio vs. Sector
The P/E ratio of Icon is 25.15, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.37.
Price to Earnings Growth Ratio
Icon has a PEG Ratio of 2.57. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Icon has a P/B Ratio of 5.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.74 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Commercial physical research

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ICLR

Previous Symbol

CUSIPN/A

CIK1060955

Webwww.iconplc.com

Phone353-1291-2000

Debt

Debt-to-Equity Ratio0.05

Current Ratio1.29

Quick Ratio1.29

Price-To-Earnings

Trailing P/E Ratio25.15

Forward P/E Ratio29.91

P/E Growth2.57

Sales & Book Value

Annual Sales$2.81 billion

Price / Sales3.26

Cash Flow$8.81 per share

Price / Cash Flow19.39

Book Value$30.91 per share

Price / Book5.52

Profitability

EPS (Most Recent Fiscal Year)$6.88

Net Income$373.99 million

Net Margins13.26%

Return on Equity24.20%

Return on Assets13.46%

Miscellaneous

Employees14,650

Outstanding Shares53,620,000

Market Cap$9.16 billion

Next Earnings Date7/22/2020 (Estimated)

OptionableOptionable

Receive ICLR News and Ratings via Email

Sign-up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter.

Icon (NASDAQ:ICLR) Frequently Asked Questions

How has Icon's stock been impacted by COVID-19 (Coronavirus)?

Icon's stock was trading at $152.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ICLR stock has increased by 12.0% and is now trading at $170.77. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Icon?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icon in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Icon.

When is Icon's next earnings date?

Icon is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Icon.

How were Icon's earnings last quarter?

Icon Plc (NASDAQ:ICLR) announced its quarterly earnings results on Wednesday, April, 22nd. The medical research company reported $1.70 earnings per share for the quarter, beating analysts' consensus estimates of $1.68 by $0.02. The medical research company earned $715.10 million during the quarter, compared to analyst estimates of $711.07 million. Icon had a return on equity of 24.20% and a net margin of 13.26%. The business's revenue was up 6.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.63 EPS. View Icon's earnings history.

What price target have analysts set for ICLR?

11 brokers have issued 1 year target prices for Icon's stock. Their forecasts range from $135.00 to $182.00. On average, they anticipate Icon's stock price to reach $159.18 in the next twelve months. This suggests that the stock has a possible downside of 6.8%. View analysts' price targets for Icon.

Has Icon been receiving favorable news coverage?

Media headlines about ICLR stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Icon earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutIcon.

Are investors shorting Icon?

Icon saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 874,200 shares, a drop of 15.1% from the April 30th total of 1,030,000 shares. Based on an average daily volume of 359,100 shares, the short-interest ratio is currently 2.4 days. Approximately 1.7% of the company's stock are short sold. View Icon's Current Options Chain.

Who are some of Icon's key competitors?

Some companies that are related to Icon include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), PRA Health Sciences (PRAH), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL) and Pieris Pharmaceuticals (PIRS). View all competitors.

What other stocks do shareholders of Icon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Icon investors own include Pfizer (PFE), Gilead Sciences (GILD), CVS Health (CVS), Mastercard (MA), NVIDIA (NVDA), Visa (V), Alibaba Group (BABA), Walt Disney (DIS), Johnson & Johnson (JNJ) and Procter & Gamble (PG).

Who are Icon's key executives?

Icon's management team includes the following people:

Dr. Steven A. Cutler, CEO & Director (Age 59)
Mr. Brendan Brennan, Chief Financial Officer (Age 40)
Jonathan Curtain, VP of Corp. Fin. & Investor Relations
Mr. Thomas O'Leary, Chief Information Officer
Mr. Diarmaid Cunningham, Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec. (Age 44)

What is Icon's stock symbol?

Icon trades on the NASDAQ under the ticker symbol "ICLR."

Who are Icon's major shareholders?

Icon's stock is owned by a number of institutional and retail investors. Top institutional shareholders include WCM Investment Management LLC (7.13%), Wellington Management Group LLP (6.68%), Clearbridge Investments LLC (5.22%), Acadian Asset Management LLC (3.96%), Comgest Global Investors S.A.S. (3.54%) and Alliancebernstein L.P. (3.53%).

Which major investors are selling Icon stock?

ICLR stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Wellington Management Group LLP, Massachusetts Financial Services Co. MA, Lord Abbett & CO. LLC, Janus Henderson Group PLC, Two Sigma Investments LP, Brown Capital Management LLC, and Canada Pension Plan Investment Board.

Which major investors are buying Icon stock?

ICLR stock was acquired by a variety of institutional investors in the last quarter, including Invesco Ltd., Zurich Insurance Group Ltd FI, WCM Investment Management LLC, Comgest Global Investors S.A.S., Clearbridge Investments LLC, Grandeur Peak Global Advisors LLC, Federated Hermes Inc., and Polen Capital Management LLC.

How do I buy shares of Icon?

Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Icon's stock price today?

One share of ICLR stock can currently be purchased for approximately $170.77.

How big of a company is Icon?

Icon has a market capitalization of $9.16 billion and generates $2.81 billion in revenue each year. The medical research company earns $373.99 million in net income (profit) each year or $6.88 on an earnings per share basis. Icon employs 14,650 workers across the globe.

What is Icon's official website?

The official website for Icon is www.iconplc.com.

How can I contact Icon?

Icon's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.

This page was last updated on 6/1/2020 by MarketBeat.com Staff